Efficacy and Safety of Daclatasvir and Sofosbuvir in Egyptian Patients with Chronic Hepatitis C Genotype 4 and Cirrhosis | ||||
| The Medical Journal of Cairo University | ||||
| Article 34, Volume 87, September, September 2019, Page 3003-3008 PDF (597.3 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/mjcu.2019.59350 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| AHMAD E. SHAMS EL-DIN, M.B.B.Ch.; MAMDOUH A. GABR, M.D.; AMR M. GAWALY, M.D.; MANAL A. EID, M.D. | ||||
| The Departments of Internal Medicine* and Clinical Pathology**, Faculty of Medicine, Tanta University | ||||
| Abstract | ||||
| Abstract Background: Hepatitis C virus (HCV) infection is a leading cause of Chronic Liver Disease (CLD) and liver transplantation globally. Currently, oral combinations of Direct Acting Anti-viral agents (DAAs) are the standard of care for treating chronic HCV infection. Aim of Study: To assess the efficacy & safety of combi-nation of Daclatasvir and Sofosbuvir in Egyptian patients with chronic hepatitis C Genotype 4 and Cirrhosis. Patients and Methods: 50 Egyptian, cirrhotic patients with HCV genotype 4 infection were treated with a generic form of sofosbuvir (SOF) 400mg, daclatasvir (DCV) 60mg with or without weight-based ribavirin (RBV) for only 12 weeks. 40 out of the 50 patients enrolled in the study, com-pleted treatment, while the remaining 10 patients were lost for follow-up. Results: The 12 weeks combination of SOF plus DCV achieved SVR in all treated patients (100%) whether treatment-naïve or experienced, with or without ribavirin. A significant improvement was observed in transaminases, while a non-significant improvement was observed in serum albumin, bilirubin, INR and the mean CTP score indicating improvement in liver functions. Regarding safety outcomes, all treatment-related AEs were only minor AEs with no major AEs. Conclusion: The combination of SOF plus DCV with or without RBV for only 12 weeks is highly effective in treating HCV GT4 cirrhotic patients with SVR12 rate of 100%, safe and well tolerated by these cirrhotic patients. Moreover, there was a marginal improvement in liver functions observed 12 weeks after treatment. | ||||
| Keywords | ||||
| H. C. V; Chronic liver disease (CLD); Cirrhosis | ||||
|
Statistics Article View: 120 PDF Download: 207 |
||||
